FY2024 EPS Estimates for ICON Public Decreased by Analyst

ICON Public Limited (NASDAQ:ICLR) – Research analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for shares of ICON Public in a research note issued on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will earn $13.25 per share for the year, down from their prior forecast of $13.34. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share.

Several other equities research analysts also recently issued reports on ICLR. Leerink Partners restated an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday. Robert W. Baird reduced their target price on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday. StockNews.com downgraded shares of ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. JPMorgan Chase & Co. cut their price objective on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Finally, Evercore ISI decreased their target price on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $292.45.

ICON Public Stock Performance

Shares of ICLR stock opened at $212.76 on Wednesday. ICON Public has a 12 month low of $183.38 and a 12 month high of $347.72. The stock has a market capitalization of $17.55 billion, a P/E ratio of 23.72, a PEG ratio of 1.45 and a beta of 1.25. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm’s 50 day moving average is $259.64 and its 200 day moving average is $298.45.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. ICON Public’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the company earned $3.10 earnings per share.

Institutional Investors Weigh In On ICON Public

A number of institutional investors have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC bought a new stake in ICON Public in the second quarter worth $54,000. ORG Partners LLC purchased a new stake in ICON Public during the 2nd quarter valued at about $59,000. GAMMA Investing LLC grew its position in ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after acquiring an additional 87 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after purchasing an additional 42 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in ICON Public by 119.6% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 226 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.